These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3561783)

  • 1. Progression of Parkinson's disease without levodopa.
    Goetz CG; Tanner CM; Shannon KM
    Neurology; 1987 Apr; 37(4):695-8. PubMed ID: 3561783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
    Fernandez HH; Odin P
    Curr Med Res Opin; 2011 May; 27(5):907-19. PubMed ID: 21351823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa and the progression of Parkinson's disease.
    Fahn S; Oakes D; Shoulson I; Kieburtz K; Rudolph A; Lang A; Olanow CW; Tanner C; Marek K;
    N Engl J Med; 2004 Dec; 351(24):2498-508. PubMed ID: 15590952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term experience with selegiline and levodopa in Parkinson's disease.
    Lieberman A
    Neurology; 1992 Apr; 42(4 Suppl 4):32-6; discussion 41-8. PubMed ID: 1584430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa in Parkinson's disease: from the past to the future.
    Pezzoli G; Zini M
    Expert Opin Pharmacother; 2010 Mar; 11(4):627-35. PubMed ID: 20163273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of DBS, premotor rTMS, and levodopa on motor function and silent period in advanced Parkinson's disease.
    Bäumer T; Hidding U; Hamel W; Buhmann C; Moll CK; Gerloff C; Orth M; Siebner HR; Münchau A
    Mov Disord; 2009 Apr; 24(5):672-6. PubMed ID: 19185021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
    Martínez-Martín P; Hernández B; Ricart J;
    Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prosody and levodopa in Parkinson's disease.
    Azevedo LL; Reis CA; Souza IS; Cardoso FE
    Arq Neuropsiquiatr; 2013 Nov; 71(11):835-40. PubMed ID: 24394867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
    Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal study of the motor response to levodopa in Parkinson's disease.
    Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
    Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spatial disorientation in Parkinson's disease: no effect of levodopa substitution therapy.
    Hovestadt A; De Jong GJ; Meerwaldt JD
    Neurology; 1988 Nov; 38(11):1802-3. PubMed ID: 3185919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications.
    Yang HJ; Ehm G; Kim YE; Yun JY; Lee WW; Kim A; Kim HJ; Jeon B
    J Neurol Sci; 2017 Jun; 377():6-11. PubMed ID: 28477709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Observational Study of the Effect of Levodopa-Carbidopa Intestinal Gel on Activities of Daily Living and Quality of Life in Advanced Parkinson's Disease Patients.
    Krüger R; Lingor P; Doskas T; Henselmans JML; Danielsen EH; de Fabregues O; Stefani A; Sensken SC; Parra JC; Onuk K; Yegin A; Antonini A
    Adv Ther; 2017 Jul; 34(7):1741-1752. PubMed ID: 28631218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression.
    Caraceni T; Scigliano G; Musicco M
    Neurology; 1991 Mar; 41(3):380-4. PubMed ID: 2006005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.